Problem Adaptation Therapy for Mild Cognitive Impairment and Depression

Depression Clinical Trial

— PATH-MCI  

Official title:

Problem Adaptation Therapy for Mild Cognitive Impairment and Depression

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03043573
• Other study ID #: 1603017114
• Secondary ID: 1R01AG050514
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 1, 2017
• Est. completion date: May 31, 2025

Study information

• Verified date: May 2024
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present collaborative R01 study, between Cornell and Johns Hopkins, aims to compare Problem Adaptation Therapy for Mild Cognitively Impaired Older Adults (PATH-MCI) vs. Supportive Therapy for Cognitively Impaired Older Adults (ST-CI) in improving cognitive, affective, and functioning outcomes.

Description:

The present collaborative R01 study, between Cornell and Johns Hopkins, aims to compare Problem Adaptation Therapy for Mild Cognitively Impaired Older Adults (PATH-MCI) vs. Supportive Therapy for Cognitively Impaired Older Adults (ST-CI) in improving cognitive, affective and functioning outcomes. Psychotherapy, also known as talking therapy, is the use of psychological methods to help a person change and overcome problems in desired ways. PATH-MCI differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver. Supportive Therapy incorporates standard of care approaches by using non-specific techniques to provide a supportive environment and help patients to express their feelings & focus on their strengths and abilities.

The investigators plan to randomize 80 treatment subjects, older adults (40 at Cornell and 40 at Johns Hopkins) with MCI-depression. 80 study partners may also be potentially recruited. Both sites have shown feasibility of recruitment, randomization, retention, and assessment procedures for patients with MCI. Cornell has shown evidence of administration of PATH in this population. Certified mental health clinicians in PATH-MCI and ST-CI will administer 15 in-office sessions in six months.

The investigators propose to compare the effects of 15 sessions (12 weekly in first 12 weeks and 3 monthly booster sessions afterwards) of PATH-MCI vs. ST-CI in 80 older adults (treatment subjects) with MCI-depression. Research assistants, unaware of study hypotheses and participant randomization status, will perform research assessments at baseline and at 6 (no cognitive measures), 12, 24, 36 (no cognitive measures) and 52 weeks after randomization.

There will also be optional blood draws at study entry, 12, and 52 weeks. The purpose of the blood draws is to better understand whether response to psychotherapy treatment is affected by genes, by inflammation, or by the possible memory factor called BDNF (brain-derived neurotrophic factor). Also, all therapy sessions will be audiotaped (if the patient consents) and Dr. Shermer (a clinician outside of the Weill Cornell Institute of Geriatric Psychiatry) will evaluate randomly selected sessions and rate the therapists' adherence and competence based on the PATH-MCI and ST Adherence Scales

The study partner will provide information about the treatment subject and participate in treatment if agreed by the treatment subject. To explore the effects of PATH-MCI on the study partner, the investigators will collect the following data from the study partner: demographic, burden (Short Zarit Burden interview), and treatment satisfaction (Client Satisfaction Questionnaire).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: May 31, 2025
• Est. primary completion date: May 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 85 Years

Eligibility

Inclusion Criteria:

• Amnestic MCI as defined by Albert et al

• Montgomery Asberg Depression Rating Scale (MADRS) greater than 7 and MADRS total less than 30

• Participants will be off antidepressants, cholinesterase inhibitors or memantine, or on a stable dosage for at least 12 weeks without any medical recommendation to adjust dosage in next 3 months (during treatment)

• Clinical Dementia Rating (CDR) = 0.5 at screening

• Subjects will have capacity to consent

Exclusion Criteria:

• Deemed to have a significant suicide risk as assessed by site PI and clinical team

• Deemed too unstable medically or neurologically to safely enroll in a research trial

• Deemed too psychiatrically unstable to safely enroll in randomized trial of psychotherapy. Requiring psychiatric hospitalization at baseline for safety.

• Current involvement in psychotherapy

• Lack of English fluency

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Cognitive Impairment
• Depression
• Depressive Disorder

Intervention

Behavioral:
• PATH-MCI
Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
• Supportive Therapy
ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.

Locations

Country	Name	City	State
United States	Johns Hopkins University School of Medicine	Baltimore	Maryland
United States	Montefiore Medical Center	Bronx	New York
United States	Weill Cornell Medicine	New York	New York
United States	Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine	White Plains	New York

Sponsors (4)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University	Johns Hopkins University, Montefiore Medical Center, National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in Stress Reduction assessed by Perceived Stress Scale	Perceived Stress Scale	Baseline, 6, 12, 24, 36, and 52 Weeks
Primary	Change in Global Cognition assessed by RBANS	Global cognition will be assessed by the Repeatable Battery for the Assessment of Neuropsychological Status Total Score (RBANS)	Baseline, 12, 24, and 52 Weeks
Secondary	Change in disability function assessed with WHODAS-II	Disability function, as measured by the World Health Organization Disability Assessment Schedule-II (WHODAS-II) Total score	Baseline, 6, 12, 24, 36, and 52 Weeks
Secondary	Change in Depression assessed by MADRS	Depression assessed by Montgomery Asberg Depression Rating Scale (MADRS) Total Score	Baseline, 6, 12, 24, 36, and 52 Weeks
Secondary	Change in Episodic Memory assessed by subscale of RBANS	Delayed Recall subscale of Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)	Baseline, 12, 24, and 52 Weeks
Secondary	Change in Executive Function assessed by Trail Making Test	Trail Making Test	Baseline, 12, 24, and 52 Weeks